Summary
Overview
Work History
Education
Skills
Certification
Research Affiliation
Clinical Research Conducted At
Research
References
Timeline
Generic

Jakora Noiles-Pesnell

Weymouth,MA

Summary

Strong leader and problem-solver dedicated to streamlining operations to decrease costs and promote organizational efficiency. Uses independent decision-making skills and sound judgment to impact company success positively.

Overview

13
13
years of professional experience
3
3
Certification

Work History

Associate Director, Business Development

Elligo Health Research, Inc.
07.2019 - Current
  • Improved overall team efficiency by streamlining project management processes and implementing new collaboration tools.
  • Spearheaded the development and launch of a new processes, leading to increased market share, client satisfaction.
  • Managed cross-functional tasks for multiple large-scale projects, successfully completing each on time and within budget constraints.
  • Established strong relationships with key industry partners, creating mutually beneficial opportunities for growth and collaboration.
  • Implemented data-driven decision-making strategies, leading to more informed business choices and positive outcomes.
  • Leveraged data and analytics to make informed decisions and drive business improvements while exceeding my annual company revenue and KPI goals.

Manager/Lead Clinical Research Coordinator

Boston Neuro Research Center (Formerly AMAC)
02.2019 - 04.2019
  • Built Increased team productivity by implementing streamlined processes and effective communication strategies.
  • Achieved departmental goals by developing and executing SOPs, strategic plans and performance metrics.
  • Reduced operational costs through comprehensive process improvement initiatives and resource management.
  • Enhanced customer satisfaction by resolving disputes promptly, maintaining open lines of communication, and ensuring high-quality service delivery.
  • Developed a strong company culture focused on employee engagement, collaboration, and continuous learning opportunities.
  • Managed budgets effectively, ensuring optimal financial performance while investing in necessary resources for business growth.
  • Reduced study deviations through meticulous documentation of informed consent processes, eligibility assessments, and visit details.
  • Worked with principal investigator and sponsors to facilitate daily trial activities and comply with research protocols.
  • Gathered, processed, and shipped lab specimens.

Site Director/Lead CRC

AMAC Research Institute LLC.
07.2017 - 02.2019
  • Established a specialized research site for a neurologist who appointed me as the Lead CRC and Site Director/Manager. In this capacity, I undertook comprehensive responsibilities, ranging from managing payroll to patient interactions. I also orchestrated the establishment of our research laboratory, procured all necessary licenses and certificates, and formulated essential Standard Operating Procedures (SOPs). Moreover, I assumed the role of staff management, ensuring the smooth operation of the site. Now named 'Boston Neuro Clinical Research Institute' - role expanded above.

Sr. Customer Support Associate

4G Clinical
11.2016 - 04.2017


  • Successfully implemented and managed the Randomization and Trial Supply Management (RTSM) system for different clinical trials, ensuring accurate and efficient patient randomization and drug supply allocation.
  • Acted as a knowledgeable liaison between research sites, sponsors, and the RTSM development team, facilitating effective communication, troubleshooting, and issue resolution.
  • Provided comprehensive customer support to research sites and sponsors utilizing the custom RTSM system by 4G Clinical, addressing inquiries, offering training, and resolving technical challenges.
  • Collaborated closely with research site staff and sponsors to gather feedback, translate user requirements, and ensure the seamless functionality of the RTSM system.
  • Demonstrated a deep understanding of the RTSM system's capabilities, delivering timely solutions to user inquiries and contributing to continuous system improvement.
  • Maintained detailed records of user interactions, inquiries, and resolutions to build a comprehensive knowledge base for future support efforts.

Sr. Clinical Research Coordinator

Beacon Clinical Research
12.2012 - 05.2016
  • Improved patient recruitment by developing and implementing targeted outreach strategies and pre-screening plans for potential research ready patients.
  • Gathered, processed, and shipped lab specimens.
  • Enhanced data quality by closely monitoring study metrics and resolving discrepancies/queries in a timely manner.
  • Streamlined study processes for increased efficiency by collaborating with cross-functional teams on protocol development and implementation.
  • Facilitated clinical trial progression, effectively managing multiple projects simultaneously.
  • Prioritized patient care and satisfaction while leading the allergy clinic, resulting in high levels of patient engagement and retention. Established rapport with patients, addressing their concerns, and ensuring a positive clinical experience.

Education

Massage Therapy & Business Management -

Lincoln Technical Institute
Brockton, MA
01.2011

Skills

  • Proposal Writing
  • Customer Retention
  • Emotional Intelligence
  • Effective Communication
  • Networking Abilities
  • Time Management
  • Relationship Building
  • Project Management
  • Adaptability
  • Conflict Resolution
  • Cross-functional Collaboration
  • Analytical Thinking

Certification

  • 2019, IATA Certification, CITI Program
  • 2019, GCP Certification, CITI Program
  • 2014, Phlebotomy Certification, Phlebotomy Services Inc.
  • 2011, Massage Therapy Certification/License, Therapeutic Massage

Research Affiliation

2019-01-01, Present, Associate Director, Business Development, Elligo Health Research, Inc., 11612 Bee Cave Road, Bldg. 1, Suites 100 and 150, Austin, TX, 78738

Clinical Research Conducted At

  • 2019-01-01, 2019-12-31, Site Manager/Lead Clinical Research Coordinator, Boston Neuro Research Center (Formerly AMAC), Dartmouth, MA
  • 2017-01-01, 2019-12-31, Site Director/Lead CRC, AMAC Research Institute LLC, N. Dartmouth, MA
  • 2012-01-01, 2016-12-31, Sr. Clinical Research Coordinator, Beacon Clinical Research, Brockton, MA

Research

  • Protocol BB-2001-201b: Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease
  • Protocol VEL-2001: A Phase 2b, Multicenter, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder in Adult Female Subjects
  • Protocol NMP-CYZ-P2-002: A Multicenter, Randomized, Double-Blind, PlaceboControlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Subjects With Type 2 Diabetes
  • Protocol AVP-786-302: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
  • Protocol PFIZER A4091059: A Phase 3, Randomized, Double Blind, Placebo And Active-Controlled, Multicenter, Parallel-Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain
  • Protocol CP007: A Double-Blind, Randomized, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
  • Protocol AMG145: Cardiovascular: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination with Statin Therapy in Patients with Clinically Evident Cardiovascular Disease
  • Protocol D589UC00001 : A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort pMDI 160/4.5 μg x 2 Actuations Twice- daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in COPD Patients
  • Protocol D1690L00026 : Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
  • Protocol LCRM112: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE GLYCEMIC EFFECTS, SAFETY, AND TOLERABILITY OF METFORMIN DELAYED-RELEASE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
  • Protocol CV181-369: A 24-Week International, Multicenter, Randomized, Open-Label, Active- Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-Administered with Dapagliflozin Compared to Insulin Glargine in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin with or without Sulfonylurea Therapy
  • Protocol B3291026: DPN: RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVE CONTROLLED PARALLEL GROUP PHASE 2 STUDY TO EVALUATE PF-05089771 AS A MONOTHERAPY AND AS AN ADD-ON TO PREGABALIN FOR THE TREATMENT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY
  • Protocol P05607/001: A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis /Rhinoconjunctivitis With or Without Asthma
  • Protocol DS5565-A-E309: Fibromyalgia: A Randomized, Double-Blind, Placebo and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia
  • Protocol DS5565-A-E312: AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA
  • Protocol FEB-XR_201: A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment
  • Protocol 20120138: A Multicenter, Controlled, Open-label Extension study to Assess the Long-term Safety and Efficacy of AMG 145
  • Protocol 20110110: A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145
  • Protocol 0653C-185: A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy of Ezetimibe/Atorvastatin 10 mg/40 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed Ezetimibe 10 mg and Atorvastatin 40 mg in Patients With Primary Hypercholesterolemia
  • Protocol B1481020: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF- 04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS
  • Protocol 27018966IBS3002: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
  • Protocol NAK-07: A 52-week, double-blind, randomized, placebo-controlled, parallel-group phase III study with re-randomization at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhea
  • Protocol I5Q-MC-CGAH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine - the EVOLVE-2 Study
  • Protocol OC-EG-302: A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain
  • Protocol LBR 101-022: A Multicenter, Double-Blind, Double-Dummy, Placebo-controlled, Parallel-Group, Multi-Dose Study comparing the Efficacy and Safety of Subcutaneous LBR101 with Placebo for the Preventative Treatment of Chronic Migraine
  • Protocol LBR 101-021: A Multicenter, Double-Blind, Placebo-controlled, Parallel-Group, Study comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR101 with Placebo for the Preventative Treatment of High Frequency Episodic Migraine
  • Protocol NB-CVOT: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR
  • Protocol 1326V9235: A Randomized Double- blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long- term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain
  • Protocol AP-01-13 A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox in Subjects with Osteoarthritis of the Knee
  • Protocol I5Q-MC-CGAF: A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 In Patients with Mild to Moderate Osteoarthritis Pain of the Knee
  • Protocol YM178-MA-1005: A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder
  • Protocol 214868-007 : A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of AGN-214868 in Patients with Postherpetic Neuralgia
  • Protocol TV-45070-CNS-20013: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients with Postherpetic Neuralgia
  • Protocol CHS-0214-04: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis
  • Protocol E2006-G000-201: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy

References

REFERENCES PROVIDED UPON REQUEST

Timeline

Associate Director, Business Development

Elligo Health Research, Inc.
07.2019 - Current

Manager/Lead Clinical Research Coordinator

Boston Neuro Research Center (Formerly AMAC)
02.2019 - 04.2019

Site Director/Lead CRC

AMAC Research Institute LLC.
07.2017 - 02.2019

Sr. Customer Support Associate

4G Clinical
11.2016 - 04.2017

Sr. Clinical Research Coordinator

Beacon Clinical Research
12.2012 - 05.2016

Massage Therapy & Business Management -

Lincoln Technical Institute

Similar Profiles

CREATE PROFILE
Jakora Noiles-Pesnell